PRLD
Prelude Therapeutics Incorporated
NASDAQ · Healthcare · Biotechnology · US
$5.46
+4.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 22.4M | 12.1M | 7.0M | — | — |
| Cost of Revenue | 391.0K | 1.7M | — | — | — |
| Gross Profit | 22.0M | 10.4M | 7.0M | — | — |
| Operating Expenses | |||||
| R&D Expense | 69.4M | 94.3M | 118.0M | 103.4M | 92.9M |
| SG&A Expense | 20.0M | 22.4M | 28.7M | 28.9M | 30.7M |
| General & Admin Expense | 20.4M | 22.4M | 28.7M | 28.9M | 30.7M |
| Selling & Marketing Expense | (391.0K) | — | — | — | — |
| Other Expenses | — | (1.7M) | — | (1.00) | — |
| Total Operating Expenses | 89.4M | 115.0M | 146.7M | 132.3M | 123.5M |
| Cost and Expenses | 89.8M | 116.7M | 146.7M | 132.3M | 123.5M |
| Operating Income (EBIT) | (67.4M) | (104.6M) | (139.7M) | (132.3M) | (123.5M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | 6.9M | 5.1M | 12.5M | 10.4M | 8.1M |
| Non-Operating Income (excl Interest) | (6.9M) | (5.1M) | (12.5M) | (10.4M) | (8.1M) |
| EBT (Pre-Tax Income) | (60.5M) | (99.5M) | (127.2M) | (121.8M) | (115.4M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (60.5M) | (99.5M) | (127.2M) | (121.8M) | (115.4M) |
| Earnings from Cont. Ops | (60.5M) | (99.5M) | (127.2M) | (121.8M) | (115.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (60.5M) | (99.5M) | (127.2M) | (121.8M) | (115.4M) |
| Per Share | |||||
| Basic EPS | ($0.79) | ($1.29) | ($1.68) | ($2.02) | ($2.27) |
| Diluted EPS | ($0.79) | ($1.29) | ($1.68) | ($2.02) | ($2.27) |
| Revenue Per Share | $0.23 | $0.16 | $0.09 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 98.4M | 77.0M | 75.8M | 60.4M | 47.4M |
| Diluted Shares Outstanding | 98.4M | 77.0M | 75.8M | 60.4M | 47.4M |
| Profitability Metrics | |||||
| EBITDA | (58.9M) | (97.8M) | (125.4M) | (120.7M) | (114.1M) |
| D&A | 1.6M | 1.7M | 1.8M | 1.2M | 1.3M |
| EBIT | (60.5M) | (99.5M) | (127.2M) | (121.8M) | (115.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026